While factors including patient population, product value and efficacy benefit, and pricing play the major roles in successful commercialization of gene and cell therapies, it is essential for drug developers to recognize when and where decisions related to production can also have an impact. The application of technology is a critical consideration in planning related to production time, scalability, and product purity and safety, as well as in expansion of target indications. Without access to skilled expertise, many drug developers risk making decisions related to production that can limit or even jeopardize commercial potential.
Upper Payment Limits (UPLs) explained
Regulatory shifts create new challenges for pharmaceutical stakeholders. Four states now have PDABs empowered to set UPLs for public payers, and three states...